Mauri most recently was the chief clinical and regulatory officer for Medtronic. She joined the company in September 2018 and was appointed to the medtech giant’s executive committee in August 2020. Mauri succeeds Richard Kuntz whose previously announced retirement takes effect on April 29.
Before joining the company, Mauri was a practicing interventional cardiologist at Brigham and Women’s Hospital for 15 years and was an investigator and professor of medicine at Harvard Medical School.
“With this appointment, we’re enabling a patient-centered approach to healthcare technology innovation at every stage of the product lifecycle,” CEO Geoff Martha said in a news release. “Dr. Mauri’s expertise and leadership connects medical and scientific intelligence, ensuring we have a clear appraisal of the medical and scientific landscape as we make investment decisions, and helping to deliver effective and reliable innovations for patients and healthcare providers.”
Mauri will lead the integration of medical expertise into the company’s business processes, which include investment decisions, business development, exploration of therapeutic areas and development of novel technologies.
“Medtronic is fortunate to have world-leading experts across diverse scientific and medical fields who provide unique insights and breakthrough discoveries. I’m excited to integrate this expertise across our company, to connect technology innovation with better health outcomes for patients,” Mauri said. “A strong scientific and patient-centered mindset across all stages of device development will enable innovation that saves and improves lives.”
